New to Moneycontrol - Sign up now
Its easy and FREE!
OR connect with
connect with
Don’t have an account?
Create One
Wed, Feb 06, 2013 at 09:05
Sun Pharma
Brokerage: Credit Suisse
Rating: Overweight
Target: Rs 840
Rationale: The doxil opportunity is still under-appreciated by the market, as it's likely to remain a low competition product and now becomes part of the base business.